ArticleThe Journal of international medical research2026
First-phase ejection fraction for evaluating early left ventricular systolic function in patients with cirrhosis.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PurposeFirst-phase ejection fraction has been established as an innovative indicator for detecting early left ventricular systolic changes. This study aimed to use first-phase ejection fraction to assess early changes in the left ventricular systolic function in patients with cirrhosis.MethodsIn this cross-sectional study, 122 patients with cirrhosis were stratified into the following groups based on Child-Turcotte-Pugh scores: group B1 (Child-Turcotte-Pugh class A, n = 35), group B2 (Child-Turcotte-Pugh class B, n = 43), and group B3 (Child-Turcotte-Pugh class C, n = 44). Thirty-nine healthy controls (group A) were enrolled for comparison. Basic information, clinical biochemical parameters, and ultrasound parameters were collected.ResultsCompared with groups A, B1, and B2, group B3 showed significantly decreased left ventricular ejection fraction (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.